Sheets Smith Wealth Management Buys 1,523 Shares of Stryker Corporation $SYK

Sheets Smith Wealth Management raised its stake in Stryker Corporation (NYSE:SYK) by 50.6% during the 2nd quarter, Holdings Channel.com reports. The firm owned 4,533 shares of the medical technology company’s stock after buying an additional 1,523 shares during the quarter. Sheets Smith Wealth Management’s holdings in Stryker were worth $1,427,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Capital Advisors Inc. OK boosted its holdings in shares of Stryker by 14.4% in the 2nd quarter. Capital Advisors Inc. OK now owns 205,253 shares of the medical technology company’s stock valued at $64,622,000 after buying an additional 25,767 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Stryker by 21.8% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock worth $846,723,000 after buying an additional 481,175 shares during the last quarter. New Mexico Educational Retirement Board raised its stake in shares of Stryker by 7.5% during the 2nd quarter. New Mexico Educational Retirement Board now owns 17,109 shares of the medical technology company’s stock worth $5,387,000 after acquiring an additional 1,200 shares in the last quarter. Mufg Securities Americas Inc. lifted its position in Stryker by 9.0% during the second quarter. Mufg Securities Americas Inc. now owns 10,392 shares of the medical technology company’s stock valued at $3,272,000 after acquiring an additional 862 shares during the last quarter. Finally, Van ECK Associates Corp boosted its stake in Stryker by 7.6% in the second quarter. Van ECK Associates Corp now owns 22,011 shares of the medical technology company’s stock valued at $6,930,000 after acquiring an additional 1,555 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 300,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director directly owned 2,301,375 shares in the company, valued at $773,031,862.50. This trade represents a 11.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 351,267 shares of company stock valued at $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

SYK has been the topic of a number of recent analyst reports. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Citigroup restated a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. BMO Capital Markets initiated coverage on Stryker in a research report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price on the stock. Finally, Raymond James Financial set a $370.00 price target on Stryker in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Stock Up 2.9%

Stryker stock opened at $331.32 on Friday. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The firm has a market cap of $127.08 billion, a price-to-earnings ratio of 34.33, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The business’s 50-day moving average price is $329.10 and its 200 day moving average price is $331.47. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.